Pfizer $PFE announced that it has terminated development of cholesterol lowering candidate bococizumab, an inhibitor of Proprotein Convertase Subtilisin Kexin type 9 (PCSK9). The data will be made available to study leaders for independent assessment with the aim of maximizing the clinical and scientific knowledge gained from the competed study.